Eli Lilly (LLY)
(Delayed Data from NYSE)
$952.74 USD
-1.43 (-0.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $950.50 -2.24 (-0.24%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Company Summary
Indianapolis, IN based Eli Lilly and Company, one of the world’s largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise.
Its pharmaceutical product categories are neuroscience (Cymbalta, Emgality and others), diabetes (Mounjaro, Zepbound, Trulicity and others), oncology (Alimta, Cyramza, Verzenio and others), immunology (Taltz and Olumiant and others) and others (Cialis and others).
Over the past ...
Company Summary
Indianapolis, IN based Eli Lilly and Company, one of the world’s largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise.
Its pharmaceutical product categories are neuroscience (Cymbalta, Emgality and others), diabetes (Mounjaro, Zepbound, Trulicity and others), oncology (Alimta, Cyramza, Verzenio and others), immunology (Taltz and Olumiant and others) and others (Cialis and others).
Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The $6.5 billion purchase of ImClone Systems in November 2008 brought with it blockbuster cancer compound, Erbitux. Its other key acquisitions include Hypnion, Inc. (a neuroscience drug discovery company focused on sleep disorders), CoLucid Pharmaceuticals (which added Reyvow for acute migraine), Loxo Oncology (added cancer drugs Retevmo and Jaypirca), Dermira (added atopic dermatitis drug Ebglyss/lebrikizumab), Akouos (expanded efforts in genetic medicines) and DICE Therapeutics (strengthened immunology pipeline).
Lilly has collaboration agreements with several companies, including Incyte (Olumiant), Boehringer Ingelheim (diabetes) and Roche (Ebglyss) among others.
Lilly divested its Elanco animal health unit as an independent publicly traded company - Elanco Animal Health Incorporated - via an initial public offering (IPO) of a minority stake in 2018. Elanco Animal Health started trading with the ticker symbol ELAN on NYSE from Sep 20. Lilly divested the remaining 80.2% stake in the new company through a “tax-efficient transaction” in March 2019.
Lilly’s 2023 revenues increased 20% to $34.1 billion. Among the key drugs, Trulicity accounted for around 20.9% of Lilly’s 2023 revenues, Mounjaro accounted for 15.1%, Verzenio 11.3%, and Taltz and Jardiance accounted for around 8.1% each of the total revenues.
General Information
Eli Lilly and Company
LILLY CORPORATE CENTER
INDIANAPOLIS, IN 46285
Phone: 317-276-2000
Fax: 317-276-4878
Web: http://www.lilly.com
Email: johnson_philip_l@lilly.com
Industry | Large Cap Pharmaceuticals |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 4.35 |
Current Year EPS Consensus Estimate | 15.77 |
Estimated Long-Term EPS Growth Rate | 20.00 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 954.17 |
52 Week High | 972.53 |
52 Week Low | 516.57 |
Beta | 0.41 |
20 Day Moving Average | 3,971,019.50 |
Target Price Consensus | 984.39 |
4 Week | 18.41 |
12 Week | 16.14 |
YTD | 63.44 |
4 Week | 14.72 |
12 Week | 8.78 |
YTD | 40.16 |
Shares Outstanding (millions) | 950.43 |
Market Capitalization (millions) | 905,508.63 |
Short Ratio | NA |
Last Split Date | 10/16/1997 |
Dividend Yield | 0.55% |
Annual Dividend | $5.20 |
Payout Ratio | 0.57 |
Change in Payout Ratio | 0.07 |
Last Dividend Payout / Amount | 8/15/2024 / $1.30 |
Fundamental Ratios
P/E (F1) | 60.40 |
Trailing 12 Months | 104.81 |
PEG Ratio | 3.02 |
vs. Previous Year | 85.78% |
vs. Previous Quarter | 51.94% |
vs. Previous Year | 35.98% |
vs. Previous Quarter | 28.91% |
Price/Book | 66.41 |
Price/Cash Flow | 124.93 |
Price / Sales | 23.26 |
6/30/24 | 67.52 |
3/31/24 | 56.98 |
12/31/23 | 51.22 |
6/30/24 | 12.76 |
3/31/24 | 10.94 |
12/31/23 | 9.94 |
6/30/24 | 1.11 |
3/31/24 | 1.35 |
12/31/23 | 0.94 |
6/30/24 | 0.87 |
3/31/24 | 1.03 |
12/31/23 | 0.73 |
6/30/24 | 21.12 |
3/31/24 | 18.32 |
12/31/23 | 16.74 |
6/30/24 | 18.86 |
3/31/24 | 17.08 |
12/31/23 | 15.36 |
6/30/24 | 23.09 |
3/31/24 | 21.04 |
12/31/23 | 19.21 |
6/30/24 | 14.35 |
3/31/24 | 13.57 |
12/31/23 | 11.44 |
6/30/24 | 1.29 |
3/31/24 | 1.32 |
12/31/23 | 1.42 |
6/30/24 | 1.74 |
3/31/24 | 1.90 |
12/31/23 | 1.69 |
6/30/24 | 63.51 |
3/31/24 | 65.57 |
12/31/23 | 62.78 |